Skip to main content
SpringerLink
Log in

EUCLID-Studie

Ticagrelor ohne Vorteil gegenüber Clopidogrel in der Sekundärprävention bei Patienten mit stabiler pAVK

EUCLID study

Ticagrelor has no advantage over clopidogrel in secondary prevention for patients with stable PAOD

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardioangiologisches Centrum Bethanien (CCB), Im Prüfling 23, 60389, Frankfurt am Main, Deutschland

    H. Eggebrecht

Authors
  1. H. Eggebrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Eggebrecht.

Ethics declarations

Interessenkonflikt

H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. EUCLID-Studie. Kardiologe 11, 17–18 (2017). https://doi.org/10.1007/s12181-016-0113-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-016-0113-1

Search

Navigation